ArsenalBio Stock
ArsenalBio is building a programmable cell therapy company to create highly effective and accessible immune cell therapies to impact outcomes for a much broader number of patients, initially those with cancer. ArsenalBio is focused on integrating technologies such as CRISPR-based genome engineering, scaled and high throughput target identification, synthetic biology, and machine learning to advance a new paradigm to discover and develop in immune cell therapies. With its programmable and computationally driven approach, ArsenalBio aspires to evolve critical metrics of success for immune cell therapies, including enhanced and broader efficacy, increased patient safety, reduced provider costs, and expanded market access.
Sign up today for more details and to buy or sell ArsenalBio Stock
Buy + SellSee Valuations and Financials
Gain insights Into ArsenalBio Stock Valuation + Share Prices
Get started to view real-time data on ArsenalBio stock including most recent valuation and historical share price information.
Get StartedArsenalBio Management Team
Director
Matthew K. Fust
Director
Brook Byers
General Counsel and Corporate Secretary
Irene Pleasure
Chief Technology Officer
Tarjei Mikkelsen
Chief People Officer
Bee Nguyen
Co-Founder, CEO, Chairman
Ken Drazan
Director
Sean Parker
Director
Valentin Barsan
Director
Beth Seidenberg
Chief Scientific Officer
W. Nicholas Haining
Chief Medical Officer
Susie Jun
Chief Technical Operations Officer
Tim Sirichoke
ArsenalBio Major Investors
Bristol-Myers Squibb Company
Byers Capital
Emerson Collective LLC
Euclidean Capital
Green Sands Equity
Hitachi America, Ltd.
Kleiner Perkins Caufield & Byers LLC (KPCB)
Osage Partners LLC
Sixth Street Partners
Softbank Vision Fund 2
The Parker Institute for Cancer Immunotherapy
UCSF Foundation Investment Company
Waycross Ventures
Westlake Village BioPartners